CD274 and neoplasm: Recent studies have demonstrated that the low-dose chemotherapeutic agent cisplatin enhances anti-PD-1/PD-L1 immunotherapy efficacy to inhibit resistant tumor growth11–13, but the mechanisms are not understood.